Guowu Wu
Impact in
-
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
-
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
Papers in
- Oncology 6
- Lung Cancer Research Studies 2
-
- Lung Cancer Treatments and Mutations 3
- Gastric Cancer Management and Outcomes 2
- Co-authors
- Heming Wu (1 shared paper)Jiaquan Li (1 shared paper)Jiajie Zhang (3 shared papers)Yuanxin Tian (1 shared paper)Chuan Huang (2 shared papers)Chunhui Huang (1 shared paper)Shanhe Wan (3 shared papers)Siming Liu (2 shared papers)
In The Last Decade
Guowu Wu
10 papers receiving 399 citations
Guowu Wu's Hit Papers
Peers
Comparison fields: 5 of 34
- Oncology 194
- Pulmonary and Respiratory Medicine 127
- Immunology 26
- Cancer Research 15
- Epidemiology 27
Countries citing papers authored by Guowu Wu
This map shows the geographic impact of Guowu Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guowu Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guowu Wu more than expected).
Fields of papers citing papers by Guowu Wu
This network shows the impact of papers produced by Guowu Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guowu Wu. The network helps show where Guowu Wu may publish in the future.
Co-authors
The 25 scholars most cited alongside Guowu Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer Hit paper breakdown → | 2024 | 233 |
| 2 | Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial Hit paper breakdown → | 2024 | 87 |
| 3 | First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial Hit paper breakdown → | 2025 | 54 |
| 4 | 2023 | 13 | |
| 5 | 2023 | 8 | |
| 6 | 2023 | 5 | |
| 7 | 2023 | 1 | |
| 8 | 2024 | 1 | |
| 9 | 2024 | 1 | |
| 10 | 2024 | 1 | |
| 11 | 2025 | 0 |
About Guowu Wu
Guowu Wu is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Genetics, Pathology and Forensic Medicine and Gastroenterology, having authored 11 papers that have together received 404 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (3 papers), Cancer Mechanisms and Therapy (2 papers), Lung Cancer Research Studies (2 papers), Glioma Diagnosis and Treatment (2 papers), Gastric Cancer Management and Outcomes (2 papers), Cancer therapeutics and mechanisms (2 papers), Chronic Myeloid Leukemia Treatments (1 paper) and Quinazolinone synthesis and applications (1 paper). The work is most often cited by research in Oncology (194 citations), Pulmonary and Respiratory Medicine (127 citations), Immunology (26 citations), Cancer Research (15 citations) and Epidemiology (27 citations). Guowu Wu has collaborated with scholars based in China and Hong Kong. Frequent co-authors include Heming Wu, Jiaquan Li, Jiajie Zhang, Yuanxin Tian, Chuan Huang, Chunhui Huang, Shanhe Wan, Siming Liu, Zhengguang Zhu and Ying Jiang. Their work appears in journals such as Nature Medicine, Bioorganic & Medicinal Chemistry, Journal of Enzyme Inhibition and Medicinal Chemistry, JAMA and Pharmaceutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.